Cresset Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Cresset Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,505	Closed	-$387K	–	869
2022 Q3	$387K	Sell	3,505 -188	-5%	-$18.9K	﹤0.01%	592
2022 Q2	$275K	Sell	3,693 -256	-6%	-$18.8K	﹤0.01%	738
2022 Q1	$309K	Sell	3,949 -1,254	-24%	-$96K	﹤0.01%	770
2021 Q4	$469K	Buy	5,203 +2,084	+67%	+$178K	﹤0.01%	719
2021 Q3	$288K	Buy	+3,119	New	+$240K	﹤0.01%	866
2019 Q2	–	Sell	-5	Closed	-$1K	–	1519
2019 Q1	$1K	Buy	+5	New	+$643	﹤0.01%	1864

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cresset Asset Management's SRPT Position: Q4 2022 in Review

Cresset Asset Management sold out of Sarepta Therapeutics (SRPT) in Q4 2022, closing a stake of 3,505 shares — an estimated $387K sold.

Cresset Asset Management first reported a position in SRPT in Q1 2019 and held it in 6 quarters. The position peaked at $469K in Q4 2021. 411 funds tracked by Wall St. Rank hold SRPT as of Q4 2022.

Cresset Asset Management reported no remaining Sarepta Therapeutics position as of Q4 2022 after selling out during the quarter.
Cresset Asset Management sold 3,505 Sarepta Therapeutics shares in Q4 2022, an estimated $387K.
Cresset Asset Management first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 6 quarters.
Cresset Asset Management's Sarepta Therapeutics position peaked at $469K in Q4 2021.
411 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2022.

Based on Cresset Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.